THE RESULTS OF THE EV06 DNA-PROTEIN COMBINATION TRIAL AND PLANS FOR GREAT, AN EDCTP2-FUNDED CONSERVED-MOSAIC EPITOPE HIV VACCINE TRIAL. (12th February 2017)

• Record Type: Journal Article
• Authors: Kaleebu, Pontiano; Levin, Jonathan; Nanvubya, Annet; Kibengo, Freddie; Jaoko, Walter; Pala, Pietro; Perreau, Matthieu; Namuniina, Annemarie; Kitandwe, Paul; Tapia, Gonzalo; Serwanga, Jennifer; Yates, Nicole; Fast, Pat; Mayer, Bryan; Montefiori, David; Tomaras, Georgia; Robb, Merlin; Lee, Carter; Wagner, Ralf; Sanders, Edward; Kilembe, William; Kiwanuka, Noah; Gilmour, Jill; Kuipers, Hester; Vooij, Dani; Chinyenze, Kundai; Priddy, Frances; Ding, Song; Hanke, Tom; Pantaleo, Giuseppe
• Is Part Of: BMJ global health. Volume 2(2017)Supplement 2
• Page Start: A16
• Page End: A16
• Publication Date: 2017-02-12
• Subjects: World health -- Periodicals; 362.105
• DOI: 10.1136/bmjgh-2016-000260.39
• Languages: English
• ISSNs: 2059-7908

Abstract

Abstract : Background: These two trials under Europe-Africa collaborations aim at addressing two factors relevant for Africa i.e helminth infections and HIV-1 diversity. EV06 used a novel combination of DNA expressing clade C Env, Gag and Pol-nef co-administered with AIDSVAX®B/E Env protein to study the effect of S. mansoni on vaccine responses. GREAT is a recently awarded trial using a 2nd generation improved conserved tHIVConsvX T-cell vaccine candidate combined with bivalent mosaic design to increase breadth and protective epitopes. Methods: EV06 enrolled 72 males and females aged 18–45, half infected with S. mansoni (SM+). In each arm 30 received vaccine and 6 placebo at week 0, 4 and 24. Responses were evaluated at week 0, 6, 26 and 36. Humoral responses were measured as binding IgG against a panel of HIV-1 envelope glycoproteins and as neutralizing antibodies (Nabs), using TZM/ bl cells and tier 1 pseudoviruses. Cellular responses were measured as HIV-specific CD4+ and CD8+ T-cell by IFN-γ ELIS-pot and multi-cytokine intracellular staining flow cytometry. GREAT will be a phase IIa trial and preparation for efficacy trials in Kenya, Uganda and Zambia testing ChAdOx1.tHIVconsv5 and ChAdOx1.tHIVconsv6 followed by MVA.tHIVconsv3 and MVA.tHIVconsv4 on week 2 (Arm 1) or week 8 (Arm 2). Progress: Differences in binding IgG response rates were observed in vaccinated participants against the vaccine matched clade C V1V2 (gp70–96ZM651.02 V1V2) at week 6: 56% among SM+ versus 86% among SM – (p=0.039). At week 36, response magnitudes were statistically lower in the SM+ against gp120 and gp140 proteins (p=0.04 for both). SM+ also had lower Nabs and ELISpot responses at various time points. Still blinded data on the first 20 volunteers show 80% responders for CD4 T cell at w26 and 70% CD8 responders at w36. These trials will provide more data on challenges facing HIV vaccine development in Africa.